Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab on Skin Barrier Function in Chinese AD Patients
NCT05624112Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by Sanofi. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05624112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624112.